Milbury Max a buys ProMis Neurosciences (PMN) shares worth $14928
PositiveFinancial Markets

Milbury Max has made a strategic investment by purchasing shares of ProMis Neurosciences for $14,928. This move highlights Milbury Max's confidence in ProMis's potential in the neuroscience sector, which is crucial for advancing treatments for neurological diseases. Such investments can signal growth opportunities in the biotech industry, making it an exciting time for stakeholders.
— Curated by the World Pulse Now AI Editorial System